Journal Watch · Journal of Controlled Release · 2026

Curcumin driven formation of self-cascade nanoclusters from urate oxidase-H<sub>2</sub>S donor conjugates for acute gouty arthritis alleviation.

We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.

Ge Y, Rong F, Wang Z et al.Journal of Controlled Release3 min readPharma relevance 50/100

DOI: 10.1016/j.jconrel.2026.114696PMID: 41655903Study type: research study

TL;DR

We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.

Key findings

  • This way, the platform could not only directly eliminate MSU, but also release the therapeutic agents, hydrogen sulfide (H<sub>2</sub>S) gas and curcumin, triggered by the toxic by-product H<sub>2</sub>O<sub>2</sub> during UOx catalysis.
  • Thus, the inflammation could be effectively restrained by the in situ co-delivery of H<sub>2</sub>S and curcumin.
  • We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.

What they did

Although administration of urate oxidase (UOx) could degrade the MSU, the toxic by-product hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) generated during the degradation would aggravate the inflammation. To surmount this, we developed a smart stimuli-responsive drug delivery platform (termed UBC) for the treatment of acute GA, where urate oxidase (UOx) was initially modified with the phenylboronic acid-based self-immolative thiocarbamate through nucleophilic substitution, and then co-assembled with curcumin through boronate bonds.

Full abstract (original)

Background: Gouty arthritis (GA) is a common arthritis characterized by chronic inflammation and monosodium urate (MSU) crystal deposition in articular structures. Current clinical medications mainly target to alleviate the inflammation, but do less to the deposited MSU.

What they did: Although administration of urate oxidase (UOx) could degrade the MSU, the toxic by-product hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) generated during the degradation would aggravate the inflammation. To surmount this, we developed a smart stimuli-responsive drug delivery platform (termed UBC) for the treatment of acute GA, where urate oxidase (UOx) was initially modified with the phenylboronic acid-based self-immolative thiocarbamate through nucleophilic substitution, and then co-assembled with curcumin through boronate bonds.

Results & conclusions: This way, the platform could not only directly eliminate MSU, but also release the therapeutic agents, hydrogen sulfide (H<sub>2</sub>S) gas and curcumin, triggered by the toxic by-product H<sub>2</sub>O<sub>2</sub> during UOx catalysis. Thus, the inflammation could be effectively restrained by the in situ co-delivery of H<sub>2</sub>S and curcumin. We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.

Abstract © the authors / Journal of Controlled Release (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.jconrel.2026.114696 · PubMed 41655903.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Controlled Release for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Controlled Release study find?

We believe this strategy provides a novel approach for the treatment of inflammation-related diseases and novel insight into the construction of multi-functional therapeutic nanomaterials from enzymes or other biomolecules.

What type of study is this?

It is a research study, published in Journal of Controlled Release in 2026. Although administration of urate oxidase (UOx) could degrade the MSU, the toxic by-product hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) generated during the degradation would aggravate the inflammation.

Where can I read the original paper?

The original is at the publisher via DOI 10.1016/j.jconrel.2026.114696. PubMed ID: 41655903. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Ge Y, Rong F, Wang Z et al.. Curcumin driven formation of self-cascade nanoclusters from urate oxidase-H&lt;sub&gt;2&lt;/sub&gt;S donor conjugates for acute gouty arthritis alleviation.. Journal of Controlled Release (2026). DOI: 10.1016/j.jconrel.2026.114696.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/curcumin-driven-formation-of-self-cascade-nanoclusters-from-urate-oxidas-114696/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides